

COVID-19 vaccines – ACIP makes recommendations for 2024-2025 vaccine administration

- On June 27, 2024, the Centers for Disease Control and Prevention's (CDC) [Advisory Committee on Immunization Practice](#) (ACIP) unanimously voted for 2024 – 2025 COVID-19 vaccines as authorized or approved by the FDA in persons ≥ 6 months of age.
- [COVID-19](#) continues to occur in the U.S. population:
 - COVID-19-associated hospitalizations and deaths occur all year around, but peak in December – February
 - COVID-19-associated hospitalizations and deaths are highest in adults aged 75 and older
 - More pediatric hospitalizations and deaths occur each year associated with COVID-19 than other select vaccine preventable diseases.
- Previously, the [FDA advised](#) that the preferred JN.1-lineage for the COVID-19 vaccines (2024 - 2025 formula) is the KP.2 strain, if feasible.

What's Next?

- The FDA will approve or authorize COVID-19 vaccines for the 2024 - 2025 season.
- The CDC's director will endorse the ACIP's recommendations.
- The 2024 - 2025 vaccines are expected to be available by mid-August to September 2024.